help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sacerdote, P.
Right arrow Articles by Panerai, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sacerdote, P.
Right arrow Articles by Panerai, A. E.

Journal of Clinical Endocrinology & Metabolism, Vol 70, 141-148, Copyright © 1990 by Endocrine Society

ARTICLES

Human monocyte chemotactic activity of calcitonin and somatostatin related peptides: modulation by chronic peptide treatment

P Sacerdote, M Bianchi and AE Panerai
Department of Pharmacology, University of Milan School of Medicine, Italy.

Neuropeptides are common mediators of the nervous and the immune systems. We investigated whether two families of peptides, calcitonin (CT) and somatostatin, posses human monocyte chemotactic activity. CT- related peptides induce a significant chemotactic response, and the potency order is: salmon CT greater than human CT greater than CT much greater than carbo-CT; CT gene-related peptide is completely inactive. This rank potency order differs from that in other systems (e.g. bone and nervous system). The chemotactic response of monocytes obtained from patients chronically treated with either salmon CT or carbo-CT is impaired, thus suggesting a phenomenon of down-regulation of a common receptor on monocytes. While somatostatin-(1-14) is completely inactive on monocyte chemotaxis, the synthetic analog SMS 201995 is extremely potent. Also, in this case the prolonged treatment of patients with SMS 201995 leads to an impaired chemotactic response.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. L. Becker, E. S. Nylen, J. C. White, B. Muller, and R. H. Snider Jr.
Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to Its Precursors
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1512 - 1525.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society